Answers are grounded in this paper and cite their sources.
Demonstrates that endothelial BMPR2 loss triggers enhanced proliferation in response to BMP9, indicating a need for careful patient selection in pulmonary arterial hypertension trials.
BMPR2 loss reverses the endothelial response to BMP9, causing enhanced proliferation. This finding has potential implications for the proposed translation of BMP9 as a treatment for pulmonary arterial hypertension and suggests the need for focused patient selection in clinical trials.
No takes yet. Share an insight, caveat, or question.
Theilmann et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: